Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as many months.

She started looking at old psychological studies exploring human nature and became fascinated by the Stanford Prison ...

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...

The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, multi-part single and multiple ascending dose clinical study is to evaluate the safety, tolerability and ...

Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...